Do you qualify for compensation? Find Out Now (30-second survey)

Onglyza, Kombiglyze and the Risk for Heart Failure

Onglyza, Kombiglyze and the Risk for Heart Failure – What They Knew, When They Knew It

In 2016 it was reported that 1 out of 11 people will suffer from diabetes and more than 30 million people in the U.S. alone have diabetes. Onglyza XR and Kombiglyze XR (saxagliptin) are oral medications used to lower blood sugar in patients with Type 2 Diabetes and are classified as DPP-4 Inhibitors. Unfortunately, these medications have been linked to heart failure, extended hospitalization, surgery, congestive heart surgery, cardiac arrest, and even death.

What They Knew

Onglyza is manufactured by the Bristol-Myers Squibb Company and was approved for market by the FDA in 2009. Kombiglyze was approved in 2010 and is manufactured by Bristol-Myers Squibb Company and AstraZeneca. Saxagliptin is a new new class of diabetic drug called dipeptidyl peptidase – IV (DPP-IV) which targets the slow release and availability of certain incretin hormones. Previous diabetic medications work by controlling hyperglycemia through stimulation of insulin that is released from the pancreas. Saxagliptin works by slowing down the incretin hormone (GLP-1) allowing for more glucose control. This lowers blood sugar levels by helping the body increase insulin production after meals.

The problem is that the GLP-1’s time in your system is approximately two minutes without Saxagliptin exposure but survives for at least three hours during exposure to this drug. Saxagliptin manipulates the hormone’s effect by enabling the process to continue for a much longer period of time than what the human body may process safely. This extended period of time can lead to the potential for critical heart complications.

When They Knew It

In December 2008, the FDA acknowledged that Saxagliptin drugs posed cardiovascular risks and stated that these companies that are creating new anti-diabetic medications for the treatment of type 2 diabetes should perform more studies to prove that the medications are safe. Unfortunately, Bristol-Myers Squibb Company and AstraZeneca ignored this request from the FDA and sold Saxagliptin for nearly five years before completing an adequately designed study focusing on the risks of heart failure, congestive heart failure, cardiac failure, and death related to those heart conditions.

At no time during the development of its Saxagliptin drugs did the pharmaceutical companies perform adequate studies to determine if their drug – and its drastic alterations of the natural incretin hormone cycle – could cause harmful effects to the heart. Such studies are essential when developing, and then marketing, diabetic drugs to diabetic individuals who are already at an increased risk for cardiovascular complications.

What Can You Do?

If you took Onglyza XR and Kombiglyze XR after 2009, were on the drug for at least 10 days, and suffered from heart failure, extended hospitalization, surgery, congestive heart surgery, cardiac arrest or a loved one died while taking this medication, then you may be able to make a claim. The pharmaceutical companies didn’t properly test this new medication before putting it on the market and now countless innocent patients have suffered from cardiac complications. Contact us today to see if we are able to help you.

Onglyza & Kombiglyze Warnings In The News

BREAKING (4/4/18): More Type 2 Diabetics add Complaints to Ongoing Onglyza Litigation

In the past month, two more Onglyza and Kombiglyze lawsuits were filed on behalf of diabetes patients who claim the manufacturer concealed information linking the diabetes drug to an increased risk of heart failure and failed to warn about its alleged potential to cause serious heart problems.

Read Full Article

10/7/17: Heart Failure Warning Added to the DPP-4 Inhibitor Class of Drugs

Sitagliptin (Januvia) is a DPP-4 antidiabetic oral agent for treating type 2 diabetes. A new warning label regarding the risk of developing heart failure in patients with cardiovascular disease was issued to this drug by the FDA in September 2017.

Read Full Article

4/5/16: FDA adds warnings about heart failure risk to labels of type 2 diabetes medicines containing saxagliptin and alogliptin

A U.S. Food and Drug Administration (FDA) safety review has found that type 2 diabetes medicines containing saxagliptin and alogliptin may increase the risk of heart failure, particularly in patients who already have heart or kidney disease. Heart failure can result in the heart not being able to pump enough blood to meet the body’s needs. As a result, we are adding new warnings to the drug labels about this safety issue.

Read Full Article

Onglyza & Kombiglyze Complaints & Damages

4/4/18: Curtis v. Bristol-Myers Squibb Co.; Astrazeneca Pharmaceuticals, LP; Mckesson Co. (KY)

The use of Saxagliptin can cause heart failure, congestive heart failure, cardiac
failure, death from heart failure, and other serious health conditions. Plaintiff ingested Saxagliptin, and as a result of use of the drug suffered injuries.

Read Full Case

7/24/17: Turner v. Bristol-Myers Squibb Co. (GA)

This is an action for damages relating to the Defendants’ design, manufacture, sale, marketing, advertising, promotion, labeling, packaging, and distribution of their drug Saxagliptin. Defendants sell their Saxagliptin drug under the brand names Onglyza and Kombiglyze XR. Saxagliptin, in any of its forms or products, including Onglyza and Kombiglyze XR, shall herein be referred to as “Saxagliptin.”

Read Full Case

12/4/17: Hardy v. Bristol-Myers Squibb Co. (AL)

The use of Saxagliptin can cause heart failure, congestive heart failure, cardiac
failure, death from heart failure, and other serious health conditions. Plaintiff ingested Saxagliptin, and as a result of use of the drug suffered injuries.

Read Full Case

GET YOUR FREE Onglyza/Kombiglyze CASE REVIEW TODAY

Onglyza & Kombiglyze settlements are now being negotiated, but there is a limited window to pursue help. If you think you, a friend, or a family member may qualify, get your free case review today… before it’s too late!

  • * Submit now to learn if you may be eligible for a cash settlement or call (800) 511-3838 now.

Free Guide Download

The Step-By-Step Guide To Taking Action

How to File for Financial Settlement After Injury from an Unsafe Drug or Device

Free Guide Download

The Step-By-Step Guide To Taking Action

How to File for Financial Settlement After Injury from an Unsafe Drug or Device

LATEST ARTICLES

Abilify: Is This Antipsychotic a Crapshoot? (Press Release)

DANVILLE, Calif., May 25, 2018A drug that causes people to gamble? This has to be a scapegoat for bad behavior or another crazy lawsuit like McDonald’s and the too hot coffee. While this sounds unbelievable, massive numbers of people have reported having compulsive behavior after taking the antipsychotic drug Abilify (aripiprazole). Even the underfunded FDA has published a safety report on May 3, 2016 warning that “compulsive or uncontrollable urges to gamble… have been reported with the use of the antipsychotic drug aripiprazole.”

(more…)

Invokana: The Diabetic Drug That Costs a Limb (Press Release)

DANVILLE, Calif., May 25, 2018 – 29 million people have type 2 diabetes in the U.S. making it big business for pharmaceutical companies. Released in 2013, Invokana was heralded as a new lifestyle drug and the “darling” of diabetic medications. It was even said to help patients lose weight and reduce high blood pressure! However, this miracle pill wasn’t all it was cracked up to be. Kaiser Permanente in California urges its doctors not to prescribe this drug and to closely monitor those patients who are on it. Dr. Steven Nissen, Chairman of Cardiovascular Medicine at the Cleveland Clinic, states that he is “uncomfortable prescribing [Invokana] in view of the amputation risk.”  He also calculated that one out of every 69 patients who takes canagliflozin for five years will have a drug-related amputation. Clearly this drug should be taken off the market since toe, foot, and partial leg amputations are twice as likely on Invokana as compared to other diabetic medications.

(more…)

Minimize Health Risks from Glyphosate Exposure in Your Food

Monsanto’s Roundup and its key ingredient glyphosate has to be one of the most controversial topics on the Internet. More than 1.8 million tons has been sprayed on crops and other vegetation in the U.S. since 1974 and two-thirds of that has been sprayed just in the last 10 years. (In fact, in 2014 farmers sprayed 1.65 billion pounds of glyphosate. That’s enough to cover every acre of cropland in the world with about a half pound of this chemical.) Many studies and international government agencies have attributed Roundup as carcinogenic – it can potentially cause cancer – and recommend that this weedkiller be avoided. 

(more…)

Periscope Group is not owned by or operated on behalf of any attorney or law firm. We are not affiliated with any drug or medical device companies. We do not host advertisements nor do we accept advertising requests. We are here to help YOU, the consumer, become better educated and supported. You pay absolutely nothing for our help. It’s as simple as that.

Periscope Group is not owned by or operated on behalf of any attorney or law firm. We are not affiliated with any drug or medical device companies. We do not host advertisements nor do we accept advertising requests. We are here to help YOU, the consumer, become better educated and supported. You pay absolutely nothing for our help. It’s as simple as that.

HON Code Certification

© All Rights Reserved • 2017 • Periscope Group, 4155 Blackhawk Plaza Circle, Suite 100, Danville, CA 94506 Legal Disclaimer

Protected by Copyscape

© All Rights Reserved • 2017 • Periscope Group, 4155 Blackhawk Plaza Circle, Suite 100, Danville, CA 94506 Legal Disclaimer

HON Code Certification